More Phase 3 disappointment in Alzheimer’s disease
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
The Phase 3 Alzheimer’s company few have heard of
Accera will soon deliver Phase 3 data on Alzheimer's disease, so why has nobody heard of them?
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.